Krystyna Czyżewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krystyna Czyżewska has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Edyta Mądry
Department of Physiology, Poznan University of Medical Sciences, 61-701 Poznań, Poland
2 shared publications - Marcelina Sperling
Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, 8 Rokietnicka Street, 61-701 Poznań, Poland
2 shared publications - Marta Pelczyńska
Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznań University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland
2 shared publications - Paweł Bogdański
Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 60-355 Poznan, Poland
2 shared publications - Teresa Grzelak
Physiology Department, Poznan University of Medical Sciences, 11 Smoluchowskiego Street, 60-179 Poznan, Poland
2 shared publications - Aniceta Ada Mikulska
Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6284
Beyond Obesity: Sex-Specific Associations of Vaspin with Metabolic Dysfunction
Background: Vaspin (SERPINA12) is an adipokine implicated in the regulation of insulin sensitivity and metabolic homeostasis. Evidence regarding its association with obesity-related metabolic disturbances remains inconsistent, and potential sex-specific differences are not fully understood. Methods: This cross-sectional study included 81 adults aged 30–60 years (38 women and 43 men), divided into a metabolic syndrome group (MS+) and a control group (MS−). Anthropometric, biochemical, total antioxidant status and blood pressure parameters were assessed, and insulin resistance was estimated using the HOMA-IR index. Results: In MS+ men, serum vaspin concentrations were higher than in MS− men (p = 0.004) and were associated with BMI, waist circumference, body fat percentage, fasting insulin, HOMA-IR, and diastolic blood pressure (p < 0.05 for all). In multivariable regression analysis (adjusted for age), insulin levels, lean body mass, and diastolic blood pressure explained up to 15.2% of the variability in serum vaspin concentrations in men (p = 0.035), whereas no significant model was observed in women. ROC (receiver operating characteristic) curve analysis demonstrated better discriminative performance of serum vaspin for identifying metabolic syndrome in men than in women (AUC: 0.784 ± 0.094 vs. 0.416 ± 0.115, respectively; p = 0.013). Conclusions: Circulating vaspin concentrations are more strongly associated with metabolic disturbances in men than in women These findings suggest that sex-specific regulation of vaspin may contribute to differences in metabolic dysfunction associated with visceral obesity. Overall, these results indicate that vaspin may reflect visceral obesity-related metabolic dysfunction rather than general adiposity. Further studies are needed to clarify the mechanistic role of vaspin and to determine whether it has potential as a biomarker of metabolic dysfunction.
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6284
Open AccessBeyond Obesity: Sex-Specific Associations of Vaspin with Metabolic Dysfunction
Background: Vaspin (SERPINA12) is an adipokine implicated in the regulation of insulin sensitivity and metabolic homeostasis. Evidence regarding its association with obesity-related metabolic disturbances remains inconsistent, and potential sex-specific differences are not fully understood. Methods: This cross-sectional study included 81 adults aged 30–60 years (38 women and 43 men), divided into a metabolic syndrome group (MS+) and a control group (MS−). Anthropometric, biochemical, total antioxidant status and blood pressure parameters were assessed, and insulin resistance was estimated using the HOMA-IR index. Results: In MS+ men, serum vaspin concentrations were higher than in MS− men (p = 0.004) and were associated with BMI, waist circumference, body fat percentage, fasting insulin, HOMA-IR, and diastolic blood pressure (p < 0.05 for all). In multivariable regression analysis (adjusted for age), insulin levels, lean body mass, and diastolic blood pressure explained up to 15.2% of the variability in serum vaspin concentrations in men (p = 0.035), whereas no significant model was observed in women. ROC (receiver operating characteristic) curve analysis demonstrated better discriminative performance of serum vaspin for identifying metabolic syndrome in men than in women (AUC: 0.784 ± 0.094 vs. 0.416 ± 0.115, respectively; p = 0.013). Conclusions: Circulating vaspin concentrations are more strongly associated with metabolic disturbances in men than in women These findings suggest that sex-specific regulation of vaspin may contribute to differences in metabolic dysfunction associated with visceral obesity. Overall, these results indicate that vaspin may reflect visceral obesity-related metabolic dysfunction rather than general adiposity. Further studies are needed to clarify the mechanistic role of vaspin and to determine whether it has potential as a biomarker of metabolic dysfunction.
- Open Access
- 27 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 768
Concentrations of Glypican-4, Irisin and Total Antioxidant Status in Women with Metabolic Syndrome: Influence of Physical Activity
Glypican-4 belongs to a group of poorly understood adipokines, with potential importance in people with metabolic syndrome, especially in groups of patients with glucose metabolism disorder. This study aimed to assess the effect of physical activity on serum glypican-4 and irisin levels and total antioxidant status (TAS) in plasma and saliva in women with metabolic syndrome (MetS). Seventy-two Caucasian women aged 25–60 were included in the study (36 women with MetS and 36 women without MetS (control group, CONTR)). The glypican-4 and irisin concentrations, total antioxidant status, glycemia, lipid profile, anthropometric parameters, and blood pressure were analyzed before and after 28 days of controlled physical activity. Serum glypican-4 and plasma TAS levels were higher (p = 0.006 and p = 0.043, respectively) on the 28th day than on the first day of the study only in the CONTR group. In the MetS group, 28 days of physical activity caused a reduction in body fat mass (p = 0.049) without changes in glypican-4, irisin, or TAS levels. In both groups, glypican-4 levels correlated positively with irisin levels and negatively with Waist-Hip Ratio (WHR), while irisin levels correlated positively with High-Density Lipoprotein Cholesterol (HDL-C) levels and negatively with waist circumference (WC) and WHR values on the 28th day of the study. To summarize, a 28-day moderate training, accompanied by a reduction in body fat mass, stabilized glypican-4 levels and TAS in female patients with MetS.
- 27 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 768
Open AccessConcentrations of Glypican-4, Irisin and Total Antioxidant Status in Women with Metabolic Syndrome: Influence of Physical Activity
Glypican-4 belongs to a group of poorly understood adipokines, with potential importance in people with metabolic syndrome, especially in groups of patients with glucose metabolism disorder. This study aimed to assess the effect of physical activity on serum glypican-4 and irisin levels and total antioxidant status (TAS) in plasma and saliva in women with metabolic syndrome (MetS). Seventy-two Caucasian women aged 25–60 were included in the study (36 women with MetS and 36 women without MetS (control group, CONTR)). The glypican-4 and irisin concentrations, total antioxidant status, glycemia, lipid profile, anthropometric parameters, and blood pressure were analyzed before and after 28 days of controlled physical activity. Serum glypican-4 and plasma TAS levels were higher (p = 0.006 and p = 0.043, respectively) on the 28th day than on the first day of the study only in the CONTR group. In the MetS group, 28 days of physical activity caused a reduction in body fat mass (p = 0.049) without changes in glypican-4, irisin, or TAS levels. In both groups, glypican-4 levels correlated positively with irisin levels and negatively with Waist-Hip Ratio (WHR), while irisin levels correlated positively with High-Density Lipoprotein Cholesterol (HDL-C) levels and negatively with waist circumference (WC) and WHR values on the 28th day of the study. To summarize, a 28-day moderate training, accompanied by a reduction in body fat mass, stabilized glypican-4 levels and TAS in female patients with MetS.